低剂量率近距离放射治疗前列腺癌后的生活质量 - 长期结果和已发表的近距离放射治疗系列中 QLQ-C30 和 QLQ-PR25 结果的文献综述。
Quality of life after low-dose rate-brachytherapy for prostate carcinoma - long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series.
机构信息
Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Department of Urology, University Medical Center Goettingen, Göttingen, Germany.
出版信息
Health Qual Life Outcomes. 2018 Jan 22;16(1):21. doi: 10.1186/s12955-018-0844-8.
BACKGROUND
Patient-reported health-related quality of life (HRQOL) differs between treatment options for prostate carcinoma. Long-term HRQOL data in brachytherapy series are scarce. Therefore, we analyzed prostate-specific and general HRQOL in patients treated with brachytherapy for prostate carcinoma after long-term follow-up.
METHODS
Two hundred ninety-six patients with prostate carcinoma were treated with brachytherapy (01/1998-11/2003). General and prostate-specific HRQOL were measured using EORTC-QLQ-C30 and EORTC-QLQ-PR25, respectively. Patients were asked to complete the questionnaires after a median follow-up of 141 (119-181) months. QLQ-C30 results were compared to the German reference population. QLQ-PR25 results were compared to an earlier follow-up after a median of 51 months (no published QLQ-PR25 reference population for comparison). Additionally, a literature review on HRQOL data in brachytherapy series was performed.
RESULTS
One hundred six (35.8%) patients were lost to follow-up, 70 (23.6%) had died. 120 (40.5%) patients were contacted. 80 questionnaires were returned (27% of the original cohort; 91% of alive patients were ≥70 years). Sexual activity declined over time (mean scores: 40.5 vs. 45.5; p = 0.006), hormonal treatment-related symptoms, problems associated with incontinence aids, and burden of obstructive urinary symptoms did not differ significantly compared to the 51-month follow-up. General HRQOL was numerically better in our cohort as compared to the German reference population (> 16% relative difference for both age strata; < 70 and ≥70 years).
CONCLUSIONS
Our results indicate that symptom-burden after long-term follow-up and associated prostate-specific HRQOL remains relatively stable from 51 to 141 months. General HRQOL in surviving patients was numerically better compared to the reference population.
背景
前列腺癌的治疗方案会导致患者报告的健康相关生活质量（HRQOL）存在差异。关于前列腺癌近距离放射治疗系列的长期 HRQOL 数据较为缺乏。因此，我们分析了接受前列腺癌近距离放射治疗后长期随访患者的前列腺特异性和一般 HRQOL。
方法
296 例前列腺癌患者接受了近距离放射治疗（1998 年 1 月至 2003 年 11 月）。使用 EORTC-QLQ-C30 和 EORTC-QLQ-PR25 分别测量一般和前列腺特异性 HRQOL。中位随访时间为 141 个月（119-181 个月）后，患者被要求完成问卷调查。将 QLQ-C30 结果与德国参考人群进行比较。将 QLQ-PR25 结果与中位随访 51 个月时的早期随访结果（无发表的 QLQ-PR25 参考人群进行比较）进行比较。此外，还对近距离放射治疗系列中 HRQOL 数据的文献进行了综述。
结果
106 例（35.8%）患者失访，70 例（23.6%）患者死亡。共联系到 120 例患者，其中 80 例患者返回问卷（原始队列的 27%；存活患者中 91%年龄≥70 岁）。性行为随时间推移而下降（平均评分：40.5 分比 45.5 分；p=0.006），激素治疗相关症状、与尿失禁辅助器具相关的问题以及阻塞性尿路症状的负担与 51 个月随访时相比没有显著差异。与德国参考人群相比，我们队列的一般 HRQOL 要好（两个年龄组的相对差异均>16%；<70 岁和≥70 岁）。
结论
我们的研究结果表明，长期随访后症状负担以及相关的前列腺特异性 HRQOL 在 51-141 个月时相对稳定。与参考人群相比，存活患者的一般 HRQOL 在数值上更好。
Zotero 插件